U.S. Pharma Tariffs: What Changed?

🔓The U.S. Section 232 pharma tariffs impose rates up to 100% on patented drugs. Importers must review HTS codes, patents & exemptions.

1. What changed?

The U.S. has introduced a new Section 232 tariff framework for certain imported pharmaceutical articles and ingredients under Presidential Proclamation 11020.

The headline figure has attracted most attention: additional tariffs can reach 100% for certain covered pharmaceutical imports.

The measures are now in operation, with the applicable treatment depending on the circumstances of the goods and the importer.

This is therefore more than a headline tariff increase. It creates a new issue for pharmaceutical businesses importing into the United States.

2. Why has the U.S. introduced the measures?

The measures form part of a wider U.S. policy response to vulnerabilities in pharmaceutical supply chains and reliance on overseas manufacturing.

The concern is not simply the value of pharmaceutical imports. It is the resilience of the U.S. pharmaceutical manufacturing base and its dependence on foreign production for certain medicines, active pharmaceutical ingredients and key starting materials.

For businesses operating internationally, this makes the measures are particularly significant.

3. Who could be affected?

The framework covers certain pharmaceutical products, active pharmaceutical ingredients and key starting materials.

It does not mean that every pharmaceutical import into the U.S. will automatically attract the headline 100% rate.

The treatment can depend on the product and the circumstances of the import. Certain pharmaceutical products and situations receive different treatment or may fall outside the additional tariff measures.

That makes understanding the scope of the rules important for companies with U.S. pharmaceutical imports.

4. The 100% tariff is not the whole story

The new framework contains several different tariff treatments.

There are provisions covering, among other things, certain patented pharmaceutical products, generic pharmaceuticals, specialty pharmaceuticals, qualifying onshoring arrangements and specific non-commercial uses such as clinical trials and R&D.

The framework also contains specific exclusions and transitional arrangements.

The result is a more complicated picture than simply asking whether a pharmaceutical product is subject to a 100% tariff.

5. Why does this matter to importers?

For pharmaceutical businesses, the financial consequences could be substantial.

An incorrect assessment could lead to unexpected duty costs, incorrect customs entries or compliance exposure.

There is also a practical challenge.

The tariff treatment needs to be reflected in the company's import processes, product data, and customs controls.

Knowing that the U.S. has introduced the measure is therefore only the starting point.

6. What should businesses consider now?

Businesses importing pharmaceutical products into the U.S. should consider:

• Which products in their portfolio could fall within the new framework?

• What tariff treatment could apply to those products?

• Are existing product and customs records sufficient to support the required treatment?

• Do broker instructions and import controls need to change?

  
  

These questions need to be considered against the company's actual products and supply chain rather than treated as a purely regulatory exercise.

7. Need to put the changes into practice?

The new U.S. pharmaceutical tariff framework is significant, but understanding the announcement is not the same as implementing it.

Our Pharma Guide to U.S. Proclamation 11020 takes the next step.